Brokers Issue Forecasts for Cytosorbents Q1 Earnings

Cytosorbents Co. (NASDAQ:CTSO) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Cytosorbents in a report released on Thursday, April 3rd. HC Wainwright analyst S. Lee expects that the medical research company will post earnings per share of ($0.08) for the quarter. HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Cytosorbents’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Cytosorbents’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.24) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.11) EPS.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. The company had revenue of $9.20 million for the quarter, compared to the consensus estimate of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%.

Several other research firms have also commented on CTSO. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Tuesday, April 1st. StockNews.com began coverage on Cytosorbents in a research report on Thursday, April 3rd. They issued a “hold” rating for the company. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Up 2.1 %

CTSO opened at $0.99 on Monday. The firm’s 50 day simple moving average is $1.06 and its two-hundred day simple moving average is $1.04. The company has a market capitalization of $61.91 million, a PE ratio of -2.75 and a beta of 1.17. Cytosorbents has a 1-year low of $0.70 and a 1-year high of $1.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06.

Hedge Funds Weigh In On Cytosorbents

A number of hedge funds have recently modified their holdings of the company. Millennium Management LLC bought a new stake in shares of Cytosorbents during the 4th quarter valued at $30,000. Renaissance Technologies LLC increased its stake in Cytosorbents by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock worth $80,000 after buying an additional 8,400 shares in the last quarter. Northern Trust Corp increased its stake in Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock worth $83,000 after buying an additional 16,701 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Cytosorbents during the fourth quarter valued at about $99,000. Finally, Geode Capital Management LLC grew its position in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.